Nuvalent (NUVL)
NASDAQ:NUVL
Top Page
Nuvalent
(NASDAQ:NUVL)
Select Model
Select Model
Rating:51Neutral
Price Target:
$102.00
▲(5.52% Upside)
Action:ReiteratedDate:02/28/26
The score is driven primarily by a strong, debt-free balance sheet that provides funding flexibility, but is materially constrained by the lack of revenue, sharply expanding losses, and accelerating cash burn. Technical indicators are neutral-to-mixed and do not meaningfully offset the fundamental cash flow risk, while valuation metrics provide limited support due to negative earnings and no dividend data.
Positive Factors
Debt-free, substantial equity base
Zero reported debt and roughly $1.25B of equity provide durable financial flexibility to fund multi-year drug development, absorb clinical setbacks, and invest in registration and launch activities without immediate leverage, supporting long-term R&D continuity.
Negative Factors
No product revenue (clinical-stage)
Absence of commercial revenue means all progress depends on R&D success and external funding; lacking proven commercial cash flows increases long-term execution and financing risk and delays ability to demonstrate sustainable profitability or unit economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free, substantial equity base
Zero reported debt and roughly $1.25B of equity provide durable financial flexibility to fund multi-year drug development, absorb clinical setbacks, and invest in registration and launch activities without immediate leverage, supporting long-term R&D continuity.
Read all positive factors
Nuvalent (NUVL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.60B
Dividend YieldN/A
Average Volume (3M)513.99K
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue GrowthN/A
EPS Growth-52.84%
CountryUS
Employees162
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.58
Shares Outstanding73,181,750
10 Day Avg. Volume534,440
30 Day Avg. Volume513,991
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)5.86
Price to Sales (P/S)0.00
P/FCF Ratio-26.57
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-20.15
Forecast
1Y Price Target
$142.85Price Target Upside47.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-5.55
Revenue Forecast (FY)$13.91M
Nuvalent Business Overview & Revenue Model
Company Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinas...
How the Company Makes Money
Nuvalent makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model primarily involves bringing its pipeline of targeted cancer therapies through clinical trials and regulatory approva...
Nuvalent Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -10.48M | 0.00 | -126.22M | -86.11M | -45.82M |
| Net Income | -425.38M | -260.76M | -126.22M | -81.85M | -46.34M |
Balance Sheet | |||||
| Total Assets | 1.41B | 1.14B | 732.38M | 482.46M | 293.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.37B | 1.12B | 719.90M | 472.16M | 288.11M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 164.37M | 71.96M | 31.82M | 19.48M | 8.79M |
| Stockholders Equity | 1.25B | 1.07B | 700.56M | 462.98M | 285.04M |
Cash Flow | |||||
| Free Cash Flow | -275.21M | -185.06M | -99.74M | -64.97M | -40.00M |
| Operating Cash Flow | -275.21M | -185.06M | -99.74M | -64.97M | -40.00M |
| Investing Cash Flow | -124.08M | -573.51M | -143.53M | -10.66M | -220.03M |
| Financing Cash Flow | 515.34M | 568.88M | 336.85M | 248.92M | 318.22M |
Nuvalent Technical Analysis
Negative
96.66
Price Trends
101.97
Negative
102.32
Negative
91.96
Positive
Market Momentum
-1.48
Positive
42.49
Neutral
50.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUVL, the sentiment is Negative. The current price of 96.66 is below the 20-day moving average (MA) of 98.87, below the 50-day MA of 101.97, and above the 200-day MA of 91.96, indicating a neutral trend. The MACD of -1.48 indicates Positive momentum. The RSI at 42.49 is Neutral, neither overbought nor oversold. The STOCH value of 50.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUVL.
Nuvalent Risk Analysis
Nuvalent disclosed 90 risk factors in its most recent earnings report. Nuvalent reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nuvalent Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $5.07B | 9.62 | 101.12% | ― | 100.88% | ― | |
54 Neutral | ― | -3.29 | -32.44% | ― | 106.27% | -43.90% | |
52 Neutral | $8.00B | -49.60 | -254.14% | ― | 65.83% | 28.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $7.60B | -17.19 | -42.07% | ― | ― | -52.84% | |
50 Neutral | $7.70B | -9.72 | 172.91% | ― | 2609.26% | -17.08% |
* Healthcare Sector Average
NUVL
Nuvalent
96.66
25.74
36.29%
CYTK
Cytokinetics
62.50
22.31
55.51%
TGTX
TG Therapeutics
31.75
-7.68
-19.48%
AXSM
Axsome Therapeutics
156.35
39.72
34.06%
RNA
Atrium Therapeutics, Inc.
13.23
-1.52
-10.31%
Nuvalent Corporate Events
M&A Transactions
Nuvalent’s Royalty Interest Acquired by Royalty Pharma
Neutral
Dec 16, 2025
Royalty Pharma plc has acquired a royalty interest in Nuvalent‘s investigational products, neladalkib and zidesamtinib, for up to $315 million from an undisclosed third party. This acquisition involves a 1.5% royalty on net sales, potentiall...
Executive/Board Changes
Ron Squarer Joins Nuvalent Board as Independent Director
Neutral
Dec 10, 2025
On December 9, 2025, Matthew Shair, Ph.D., resigned from the board of directors of Nuvalent, Inc., a decision not due to any disagreement with the company’s operations or policies. Subsequently, on December 10, 2025, Ron Squarer was elected ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.